BioCryst Pharmaceuticals (NASDAQ:BCRX) Hits New 52-Week High – What’s Next?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s stock price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $10.48 and last traded at $10.6090, with a volume of 1360689 shares. The stock had previously closed at $10.00.

Analyst Ratings Changes

A number of research firms have commented on BCRX. Citizens Jmp upped their target price on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research report on Thursday, May 7th. Needham & Company LLC reduced their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Wedbush reduced their price target on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Wall Street Zen lowered shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $20.70.

BioCryst Pharmaceuticals Trading Up 1.4%

The stock has a market cap of $2.58 billion, a PE ratio of -5.72 and a beta of 0.57. The company has a fifty day moving average of $8.88 and a 200-day moving average of $8.23.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The firm had revenue of $156.41 million for the quarter, compared to analyst estimates of $151.12 million. During the same period in the previous year, the company posted $0.20 EPS. BioCryst Pharmaceuticals’s revenue was up 7.5% on a year-over-year basis. As a group, research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.66 earnings per share for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of BioCryst Pharmaceuticals by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock valued at $173,732,000 after purchasing an additional 482,494 shares during the period. RA Capital Management L.P. purchased a new stake in BioCryst Pharmaceuticals during the 4th quarter worth approximately $123,452,000. Deerfield Management Company L.P. increased its stake in BioCryst Pharmaceuticals by 159.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock worth $92,363,000 after buying an additional 7,477,000 shares during the period. State Street Corp lifted its holdings in BioCryst Pharmaceuticals by 12.9% during the 4th quarter. State Street Corp now owns 11,073,211 shares of the biotechnology company’s stock worth $86,371,000 after buying an additional 1,265,773 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in BioCryst Pharmaceuticals by 20.3% during the 1st quarter. Janus Henderson Group PLC now owns 8,908,506 shares of the biotechnology company’s stock worth $84,854,000 after buying an additional 1,504,120 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.